CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 14, 2007 - CombinatoRx,
Incorporated (NASDAQ: CRXX) today announced the presentation of
additional data related to its immuno-inflammatory product
candidates, CRx-102 and CRx-139, at the European League Against
Rheumatism (EULAR) Annual Congress of Rheumatology meeting, June
13-16, 2007 in Barcelona, Spain.
CRx-102
In a poster entitled "Inhibition of Macrophage and Chondrocyte
Inflammatory Mediators by CRx-102, a Novel Synergistic Combination
Drug Candidate", Fraser, et.al. further insights into the novel
mechanism of action of CRx-102 were unveiled. The synergistic
combination of the two agents, dipyridamole and prednisolone, was
found to modulate converging intracellular signaling pathways to
synergistically inhibit key inflammatory modulators and mediators
(TNF-alpha, MIP-1a, RANTES, MDC, IL-6 and MMP-9) that control
disease progression and contribute directly to disease
pathology.
In a poster entitled "Response and State-Attainment Criteria in
Hand OA: Analysis from a Placebo-Controlled Clinical Trial of
CRx-102, A Novel Synergistic Combination Therapy", Kvien, et.al.,
reliable outcome measures to evaluate clinically meaningful
benefits of CRx-102 treatment in osteoarthritis (OA) from an
individual patient perspective were evaluated. CRx-102 consistently
showed clinically meaningful benefit across these outcome measures
and responder analyses:
-- BLISS response of individual pain of less than or equal to 20
(27% CRx-102 vs. 6% placebo, p=0.035)
-- Modified OMERACT-OARSI response (50% CRx-102 vs. 30% placebo,
p=NSS)
-- AUSCAN 20/50/70 (AUSCAN 70: 23% CRx-102 vs. 3% placebo,
p=0.037)
In a satellite symposium presentation, Dr. John Kirwan, of the
Bristol Royal Infirmary in the UK and principal investigator in the
CRx-102 phase 2a rheumatoid arthritis (RA) trial, gave a talk
entitled "A Therapy Rejuvenation: Glucocorticoids in Arth
'"/>
Page: 1 2 3 4 Related medicine technology :1.
Portola Pharmaceuticals Announces Positive Phase II EXPERT Results
and Additional Oral and Poster Presentations at the XXI Congress of
the International Society on Thrombosis and Haemostasis (ISTH)2.
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib3.
Further Statistical Analysis of the Recent Phase III trial on Lead
Product M6G Shows Additional Benefits4.
Novel Mechanism Insights and Additional Data on CombinatoRx Drug
Candidates to Be Presented at Upcoming EULAR Meeting5.
Elixir Pharmaceuticals Presents Additional Preclinical Data
Demonstrating the Potential of Ghrelin Antagonism to Regulate
Metabolism, Body Weight and Glycemic Control6.
Additional New Data from Satraplatin SPARC Phase 3 Investigational
Trial Presented at ASCO Annual Meeting7.
Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of
GVAX Immunotherapy for Pancreatic Cancer8.
Additional New Data from Satraplatin SPARC Phase 3 Investigational
Trial Presented at ASCO Annual Meeting9.
New Study Results Provide Additional Data about Short- and
Long-Term Use of Desvenlafaxine Succinate in the Treatment of
Adults with Major Depressive Disorder10.
Additional Efficacy Data from Satraplatin SPARC Phase 3
Investigational Trial Presented at Annual Meeting of American
Urological Association11.
PTC Therapeutics Announces Additional Positive Interim Phase 2
Results of PTC124 in Duchenne Muscular Dystrophy